Advertisement

Ads Placeholder
Loading...

Abivax S.A.

ABVXNASDAQ
Healthcare
Biotechnology
$118.37
$3.40(2.96%)
U.S. Market opens in 27h 44m

Abivax S.A. (ABVX) Stock Overview

Explore Abivax S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7.8B
P/E Ratio-22.13
EPS (TTM)$-5.55
ROE-1.59%
Fundamental Analysis

AI Price Forecasts

1 Month$119.07
3 Months$91.91
1 Year Target$135.50

ABVX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Abivax S.A. (ABVX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $135.50.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -22.13 and a market capitalization of 7.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.96%
5-Day Change
9.36%
1-Month Change
6.54%
3-Month Change
-11.51%
6-Month Change
41.05%
Year-to-Date (YTD) Change
-11.51%
1-Year Change
1944.39%
3-Year Change
1326.14%
5-Year Change
1326.14%
All-Time (Max) Change
1326.14%

Contact Information

33 1 53 83 08 41
5, rue de la Baume, Paris, NaN, 75008

Company Facts

690 Employees
IPO DateOct 20, 2023
CountryFR
Actively Trading

Frequently Asked Questions